Vaccine candidate spurs elusive type of broadly neutralizing HIV antibodies

FHS
May 17, 2024
4:44 pm

An HIV vaccine candidate developed at the Duke Human Vaccine Institute triggered low levels of an elusive type of broadly neutralizing HIV antibodies among a small group of people enrolled in a 2019 clinical trial.

STRUCTURE and MAXA – Biotech Investments

Kuros Biosciences AG / Key word(s): Study/Study results 27-Dec-2023 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer

December 28, 2023

An Arm and a Leg: How a surprise bill can hitch a ride to the hospital

How did three siblings who took identical ambulance rides (from the same car wreck to the same hospital) end up with three wildly different bills?

August 16, 2023

Opinion | How Do We Hack the Problem of Health Information Hacking?

Fred Pelzman is an associate professor of medicine at Weill Cornell, and has been a practicing internist for nearly 30 years. He is medical director

December 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.